Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG-Reference-Cited by-同舟云学术

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

Published:2023-07 Issue: Volume:188 Page:140-151
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zaremba Anne,Mohr Peter,Gutzmer Ralf,Meier Friedegund,Pföhler Claudia,Weichenthal Michael,Terheyden Patrick,Forschner Andrea,Leiter Ulrike,Ulrich Jens,Utikal Jochen,Welzel Julia,Kaatz Martin,Gebhardt Christoffer,Herbst Rudolf,Sindrilaru Anca,Dippel Edgar,Sachse Michael,Meiss Frank,Heinzerling Lucie,Haferkamp Sebastian,Weishaupt Carsten,Löffler Harald,Kreft Sophia,Griewank Klaus,Livingstone Elisabeth,Schadendorf Dirk,Ugurel Selma,Zimmer Lisa

Funder

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. A landscape of driver mutations in melanoma;Hodis;Cell,2012

2. Genomic Classification of Cutaneous Melanoma;Cell,2015

3. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?;Albino;Nature,1984

4. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2012

5. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma;Devitt;Pigment Cell Melanoma Res,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

2. Integrating Single-Cell and Bulk Rna Sequencing to Identify Disulfidptosis-Related Gene Signature, Immune Landscape, and Immunotherapy Targets in Cutaneous Melanoma;2024

3. Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma;2024

4. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24